Research progress of intraarticular injection of nano-microspheres in the treatment of osteoarthritis
10.3760/cma.j.cn121113-20240531-00323
- VernacularTitle:关节内注射纳米微球在骨关节炎治疗中的研究进展
- Author:
Zebin WANG
1
;
Yizhou GE
1
;
Yaokan ZHANG
1
;
Wei WU
1
;
Chen YU
1
;
Jungang LI
1
;
Yongli XU
1
;
Peng ZHANG
1
;
Zhe YANG
1
;
Feng CHANG
1
Author Information
1. 山西医科大学附属省人民医院骨科，太原 030012
- Publication Type:Journal Article
- Keywords:
Microspheres;
Osteoarthritis;
Cartilage, articular;
Inflammation;
Biocompatible materials
- From:
Chinese Journal of Orthopaedics
2025;45(6):387-392
- CountryChina
- Language:Chinese
-
Abstract:
This article reviews the benifits and challenges of nano-microspheres (NPs) in the treatment of osteoarthritis (OA). OA is a degenerative disease associated with aging, trauma, and excessive loading, with treatment strategies including basic therapy, drug therapy, reparative therapy, and reconstructive surgery. As emerging nanomaterials, NPs offer unique advantages in promoting cartilage repair due to their high surface area, excellent drug-loading capacity, and good biocompatibility. These advantages include facilitating chondrocyte generation through magnetic-mechanical control of mesenchymal stem cell microspheres and enhancing antioxidant levels using biomimetic liposomal NPs combined with glucosamine. Additionally, NPs can effectively modulate inflammatory responses, such as by inhibiting the formation of M1 macrophages and promoting their polarization to the M2 type to alleviate inflammation. Some NPs also enhance joint lubrication and relieve pain, such as hyaluronic acid-based NPs modified with choline phosphate groups. However, the application of NPs faces challenges such as high production costs, poor biocompatibility for certain types, and unknown long-term safety. Despite these challenges, with advancements in nanotechnology and a deeper understanding of the pathological mechanisms of OA, NPs are expected to provide new therapeutic approaches and more comprehensive and effective treatment options for OA patients in the future.
